Preserve the US interchangeable standard that has helped drive physician and patient confidence in biosimilars

Author byline as per print journal: Michael S Reilly, Esq Abstract: The US Food and Drug Administration (FDA) proposed eliminating the distinction between biosimilars and interchangeable biosimilars with the stated… Read More »